ReviewFrontiers in pharmacology2025
A comprehensive review on indigenous therapeutic approaches in kidney care using Ayush medicine.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bacterial Metabolite-Derived NDM-1 Inhibitors: A Computational Strategy to Overcome β-Lactam Resistance.Probiotics and antimicrobial proteins · 2026Article
- Cardioprotective potential of Maharishi Amrit Kalash: a scoping review of evidence from experimental and clinical studies.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) presents a significant global health concern due to its progressive impact on kidney function, and associated complications. This narrative review highlights the role of traditional system of medicine and comprehensive approach to managing chronic kidney disease (CKD) including their molecular mechanisms and therapeutic roles. The interdependence of physical, mental, and spiritual wellbeing is acknowledged by AYUSH, and other indigenous traditions, which emphasize on botanical drugs with proven nephroprotective qualities in addition to dietary changes, lifestyle adjustments, and mind-body therapies. For instance, traditional botanical drugs have shown nephroprotective effects in both preclinical and clinical trials. Yoga activities promote overall wellbeing, which is particularly beneficial for individuals with chronic kidney disease. Our aim is to explore and integrate traditional medicine with modern nephrology practices for enhancing CKD management. However, the review presents the brief importance of this integration and challenges such as the need for robust clinical trials to substantiate safety and efficacy. It also discusses the legal and quality control concerns related to botanical drugs. Overcoming these hurdles is paramount for the successful assimilation of traditional medicine systems with modern healthcare practices. The review also contains the synergistic blend of contemporary nephrology with ancient healing systems like AYUSH offering a compelling approach to CKD treatment and nephroprotection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.